StockNews.AI
PHAT
StockNews.AI
3 days

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

1. Frazier Life Sciences to file Schedule 13D today regarding ownership. 2. Filing indicates administrative changes, not reduced ownership in PHAT. 3. Differences in previous filings relate to reporting, not share sales. 4. Phathom focuses on treatments for gastrointestinal diseases with vonoprazan. 5. No immediate share selling impacts observed from the Frazier filing.

3m saved
Insight
Article

FAQ

Why Neutral?

The Frazier filing clarifies ownership but doesn't indicate reduced investment, maintaining current value.

How important is it?

Clarification of ownership can impact investor confidence, but no immediate changes.

Why No Impact?

No sales or changes in shareholder positions suggest long-term stability.

Related Companies

FZRSPFEJNJ
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom. While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier’s reporting approach and not to any sale of shares.  About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

Related News